Lymphoseek approved to help locate lymph nodes

March 13, 2013

(HealthDay)—The injected imaging drug Lymphoseek (technetium Tc 99m tilmanocept) has been approved by the U.S. Food and Drug Administration to help surgeons locate the lymph nodes among people with breast cancer or melanoma.

The lymph nodes filter lymphatic fluid that flows throughout the body. This fluid may contain if it has passed through diseased tissue, the FDA said in a news release. By surgically examining the lymph nodes, doctors may be able to conclude if cancer has spread.

Lymphoseek is an imaging drug that helps locate the lymph nodes, but it is not a drug, the agency stressed. It's the first lymph-node mapping drug to be approved by the FDA in 30 years.

The drug's safety and effectiveness were established in clinical trials involving 332 people with melanoma or breast cancer. The most common adverse reactions reported were pain and/or irritation at the injection site.

Lymphoseek is marketed by Navidea Biopharmaceuticals, based in Dublin, Ohio.

Explore further: Evidence strengthens link between NSAIDs and reduced cancer metastasis

More information: The FDA has more about this approval.

Related Stories

New signaling pathway linked to breast cancer metastasis

April 2, 2012

Lymph nodes help to fight off infections by producing immune cells and filtering foreign materials from the body, such as bacteria or cancer cells. Thus, one of the first places that cancer cells are found when they leave ...

Recommended for you

Elephants provide big clue in fight against cancer

October 9, 2015

Carlo Maley spends his time pondering pachyderms—and cactuses and whales, and a wide array of non-human species—all in pursuit of the answer to this question: Why do some life forms get cancer while others do not?

Compound doubles up on cancer detection

October 8, 2015

Tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer, according to a study published last week in the Proceedings of the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.